The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Kennedy's decision to "retire" the previous panel was widely decried by doctors' groups and public health organizations.

For this reason, the CDC recommends adults 50 or older schedule the following vaccines, which many people can get for free.

Public health and infectious disease experts said they were surprised and confused about the move, and questioned why the HHS did not offer any reasoning for its decision.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18 ...

aNational Institute for Health and Care Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, UK bFaculty of Medicine ...

ucl.ac.uk Respiratory syncytial virus (RSV) is the most common single cause of respiratory hospitalisation of infants and is the second largest cause of lower respiratory infection mortality worldwide ...

The CDC's Advisory Committee on Immunization Practices ... ages 50 to 59 be vaccinated for respiratory syncytial virus (RSV), and also added a new option for meningococcal vaccination.

In a significant move to curb the global burden of respiratory syncytial virus (RSV), the World Health Organization (WHO) has released its first-ever position paper on immunization strategies to ...

Researchers found that the odds of any acute cardiovascular event were higher in RSV hospitalizations vs boosted COVID-19 hospitalizations. HealthDay News — Patients with respiratory syncytial ...

Odds of any acute cardiovascular event increased when compared with COVID-19 hospitalizations in boosted and unboosted individuals. HealthDay News — Patients with respiratory syncytial virus ...